EUCTR2007-000543-98-IT进行中（未招募）不适用
SWEET-ACS INTENSIFIED MULTIFACTORIAL INTERVENTION ON HYPERGLYCEMIC PATIENTS WITH ACUTE CORONARY SYNDROMES - SWEET ACS
A. N. M. C. O. - FONDAZIONE ITALIANA LOTTA MALATTIE CARDIOVASCOLARI0 个研究点开始时间: 2007年6月14日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients of any age and gender - ACS with or without ST elevation [abnormal ischemic EKG changes (ST-elevation, ST depression, negative T waves or new LBBB)] and positive cardiac markers within 24 hours from the onset of symptoms - whole-blood glucose on admission in CCU >=140 mg/dl. - Informed consent at enrollment is required to be included in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Unstable angina (ACS without EKG and cardiac biomarkers abnormalities); - Former history of type 1 diabetes; - Hepato-biliary obstructive disease or other severe liver disease; - End-stage renal disease (dialysis or indication for kidney transplantation is required); - Terminal illness or co-morbidities with life expectancy <24 months; - Conditions associated with poor compliance with the study (alcoholism, mental illness, or drug dependence, etc.); - Unwilling to participate to the study or already enrolled in other interventional protocols.
研究者
相似试验
招募中
Unknown
A clinical study to evaluate safety and performance of absorbable, gelatin-based hemostat in patients undergoing different types of surgeries.CTRI/2024/01/061742Aegis Lifesciences Pvt. Ltd.
招募中
1 期
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Nonsmall Cell Lung Cancer (NSCLC)on-small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-503357-35-00AstraZeneca AB140
尚未招募
4 期
This study is conducted to check the safety and efficacy of Ranibizumab in participants with Retinopathy of Prematurity.CTRI/2023/07/055699Intas Pharmaceuticals Limited
招募中
4 期
A Study to Investigate Safety, Efficacy and Immunogenicity of Denosumab in Patients with Bone Metastases from Advanced MalignanciesCTRI/2023/01/049158Intas Pharmaceuticals Limited
已完成
3 期
A trial looking at the treatment of children and young people with non-rhabdomyosarcoma soft tissue sarcomasSoft tissue sarcomaCancerTopic: National Cancer Research NetworkSubtopic: Sarcoma, Paediatric OncologyDisease: Soft TissueISRCTN55318937Central Manchester University Hospitals NHS Foundation Trust40